ArticleInvestigative ophthalmology & visual science2025
Monosomy 3 Prediction by Clinical Features and BAP1 Staining and Its Value When Integrated in Liverpool Uveal Melanoma Prognosticator Online (LUMPO3).
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To predict monosomy 3 (M3) in uveal melanoma with clinical and histopathological features, including nuclear BRCA1-associated protein 1 immunohistochemistry (nBAP1-IHC), and to evaluate its prognostication performance in the Liverpool Uveal Melanoma Prognosticator Online (LUMPO3) algorithm. Methods: Patients with uveal melanoma excluding iris melanoma were included. Clinical, genetic, and histopathological features, including nBAP1-IHC, were obtained and used to construct an M3 prediction model. Two simplified models mimicking the scenario where only histology or cytology specimens are available were obtained by simplification of the full model; the M3 status predicted by these models was introduced into LUMPO3 to evaluate the performance against the standard LUMPO3 with genetic testing-based M3 status. Results: Data from 2521 patients were used to construct the M3-prediction model. nBAP1-IHC was the most significant predictor (χ2 = 128, P < 0.0001). The simplified M3-prediction models maintained the area under the receiver operating curve at 88%, with Youden sensitivity at 79% and specificity at 82%. Predicted-M3-based LUMPO3 showed that 83% (cytology-based) and 87% (histology-based) of the prognostications fell within ±10% on the metastatic mortality scale of the genetic-based LUMPO3. The designations of metastatic surveillance group, using 3%, 5%, or 10% metastatic mortality prognostication as thresholds, were identical in 96.9%, 95.8%, and 92.5%, respectively (cytology-based), and 97.1%, 95.9%, and 93.8%, respectively (histology-based), using either the genetic-M3-based LUMPO3 or the predicted-M3-based LUMPO3. Conclusions: M3 can be accurately predicted using clinical and histopathological features, of which nBAP1-IHC is the most significant predictor. The predicted-M3-based LUMPO3 and the genetic-M3-based LUMPO3 are highly consistent in terms of survival prognostication and surveillance planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.